Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:polysaccharide derivative
go back to main search page
Accession:CHEBI:65212 term browser browse the term
Definition:A carbohydrate derivative that is any derivative of a polysaccharide.
Synonyms:related_synonym: polysaccharide derivatives


show annotations for term's descendants           Sort by:
chondroitin sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FGF10 fibroblast growth factor 10 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein CTD PMID:14699094 NCBI chr16:28,695,465...28,779,953
Ensembl chr16:28,695,470...28,777,509 		JBrowse link
G FGF18 fibroblast growth factor 18 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein CTD PMID:14699094 NCBI chr16:52,724,867...52,760,246
Ensembl chr16:52,725,356...52,759,791 		JBrowse link
G FGF2 fibroblast growth factor 2 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein CTD PMID:14699094 NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916 		JBrowse link
G MDK midkine affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein CTD PMID:14699094 NCBI chr 2:16,130,787...16,133,791
Ensembl chr 2:16,130,788...16,133,510 		JBrowse link
G PTN pleiotrophin affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein CTD PMID:14699094 NCBI chr18:12,219,708...12,309,045
Ensembl chr18:12,219,787...12,309,044 		JBrowse link
dermatan sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FGF10 fibroblast growth factor 10 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein CTD PMID:14699094 NCBI chr16:28,695,465...28,779,953
Ensembl chr16:28,695,470...28,777,509 		JBrowse link
G FGF18 fibroblast growth factor 18 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein CTD PMID:14699094 NCBI chr16:52,724,867...52,760,246
Ensembl chr16:52,725,356...52,759,791 		JBrowse link
G FGF2 fibroblast growth factor 2 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein CTD PMID:14699094 NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916 		JBrowse link
G MDK midkine affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein CTD PMID:14699094 NCBI chr 2:16,130,787...16,133,791
Ensembl chr 2:16,130,788...16,133,510 		JBrowse link
G PTN pleiotrophin affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein CTD PMID:14699094 NCBI chr18:12,219,708...12,309,045
Ensembl chr18:12,219,787...12,309,044 		JBrowse link
dextran sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASP1 caspase 1, apoptosis-related cysteine peptidase multiple interactions
increases expression		 EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 mRNA]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein		 CTD PMID:30270565 NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328 		JBrowse link
G IL18 interleukin 18 increases expression
multiple interactions		 EXP Dextran Sulfate results in increased expression of IL18 mRNA
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA]		 CTD PMID:30270565 NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219 		JBrowse link
G LOC110258578 interleukin-1 beta-like multiple interactions
increases expression		 EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL1B mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA] CTD PMID:30270565
G NLRP3 NLR family pyrin domain containing 3 multiple interactions
increases expression		 EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]
Dextran Sulfate results in increased expression of NLRP3 mRNA; Dextran Sulfate results in increased expression of NLRP3 protein		 CTD PMID:30270565 NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228 		JBrowse link
G PYCARD PYD and CARD domain containing multiple interactions
increases expression		 EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein
Dextran Sulfate results in increased expression of PYCARD mRNA; Dextran Sulfate results in increased expression of PYCARD protein		 CTD PMID:30270565 NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786 		JBrowse link
fucoidan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G TNF tumor necrosis factor multiple interactions EXP [laminaran co-treated with fucoidan co-treated with Minerals] promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] CTD PMID:21948611 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416 		JBrowse link
heparin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PSP-I porcine seminal protein I multiple interactions EXP zinc chloride promotes the reaction [PSP-I protein binds to Heparin]; Zinc promotes the reaction [PSP-I protein binds to Heparin] CTD PMID:16819821 NCBI chr14:132,302,376...132,309,388
Ensembl chr14:132,302,352...132,308,106 		JBrowse link
hyaluronic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G EGFR epidermal growth factor receptor multiple interactions EXP EGFR protein affects the chemical synthesis of and affects the localization of Hyaluronic Acid CTD PMID:21520325 NCBI chr 9:139,302,410...139,474,632
Ensembl chr 9:139,300,022...139,475,589 		JBrowse link
lipopolysaccharide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP [Flavones co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein CTD PMID:31669396
G ALB albumin decreases expression EXP Lipopolysaccharides results in decreased expression of ALB protein CTD PMID:19477247 NCBI chr 8:69,643,427...69,663,152
Ensembl chr 8:69,531,487...69,721,696 		JBrowse link
G BAX BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of BAX protein
Flavones inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]		 CTD PMID:31669396 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140 		JBrowse link
G BCL2 BCL2 apoptosis regulator increases expression EXP Lipopolysaccharides results in increased expression of BCL2 mRNA CTD PMID:21645290 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879 		JBrowse link
G CASP3 caspase 3 increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of CASP3 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein]; [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein; Flavones inhibits the reaction [Lipopolysaccharides results in increased expression of CASP3 protein]; MAP1LC3B protein affects the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein]		 CTD PMID:31669396 PMID:32877744 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213 		JBrowse link
G CASP6 caspase 6 decreases expression EXP Lipopolysaccharides results in decreased expression of CASP6 mRNA CTD PMID:21645290 NCBI chr 8:112,519,450...112,534,315
Ensembl chr 8:112,520,629...112,537,045 		JBrowse link
G CAT catalase decreases expression
multiple interactions		 EXP Lipopolysaccharides results in decreased expression of CAT mRNA
Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of CAT mRNA]		 CTD PMID:36549457 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452 		JBrowse link
G CCL2 chemokine (C-C motif) ligand 2 multiple interactions EXP [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA] CTD PMID:30708112 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026 		JBrowse link
G CCL20 C-C motif chemokine ligand 20 multiple interactions EXP [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CCL20 mRNA] CTD PMID:30708112 NCBI chr15:129,172,743...129,176,069 JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator decreases expression EXP Lipopolysaccharides results in decreased expression of CFLAR mRNA CTD PMID:21645290 NCBI chr15:104,780,744...104,835,631
Ensembl chr15:104,781,616...104,835,630 		JBrowse link
G CLDN1 claudin 1 decreases expression
multiple interactions		 EXP Lipopolysaccharides results in decreased expression of CLDN1 mRNA; Lipopolysaccharides results in decreased expression of CLDN1 protein
[deoxynivalenol co-treated with Lipopolysaccharides] results in decreased expression of CLDN1 mRNA; [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]		 CTD PMID:22092031 PMID:32877744 PMID:37271275 NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 increases secretion
multiple interactions
increases expression		 EXP Lipopolysaccharides results in increased secretion of CXCL8 protein
3',4',5'-trimethoxyflavone analog inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL8 mRNA]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; fumonisin B1 promotes the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CXCL8 mRNA]; Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL8 protein		 CTD PMID:15912099 PMID:26180592 PMID:27861533 PMID:30708112 NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861 		JBrowse link
G DIABLO diablo IAP-binding mitochondrial protein decreases expression EXP Lipopolysaccharides results in decreased expression of DIABLO mRNA CTD PMID:21645290 NCBI chr14:30,498,885...30,519,846
Ensembl chr14:30,498,900...30,520,070 		JBrowse link
G GPX1 glutathione peroxidase 1 decreases expression EXP Lipopolysaccharides results in decreased expression of GPX1 mRNA CTD PMID:36549457 NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433 		JBrowse link
G GRHPR glyoxylate and hydroxypyruvate reductase affects expression EXP Lipopolysaccharides affects the expression of GRHPR mRNA CTD PMID:21645290 NCBI chr 1:238,139,764...238,151,631
Ensembl chr 1:238,139,794...238,152,382 		JBrowse link
G H2AX H2A.X variant histone increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of H2AX protein
Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of H2AX protein]		 CTD PMID:36549457 NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084 		JBrowse link
G HSPA14 heat shock protein family A (Hsp70) member 14 affects expression EXP Lipopolysaccharides affects the expression of HSPA14 mRNA CTD PMID:21645290 NCBI chr10:46,908,161...46,935,323
Ensembl chr10:46,904,311...46,935,280
Ensembl chr10:46,904,311...46,935,280 		JBrowse link
G IFNG interferon gamma increases expression EXP Lipopolysaccharides results in increased expression of IFNG mRNA CTD PMID:15998543 NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670 		JBrowse link
G IL10 interleukin 10 increases expression EXP Lipopolysaccharides results in increased expression of IL10 mRNA CTD PMID:15998543 NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378 		JBrowse link
G IL12A interleukin 12A increases expression EXP Lipopolysaccharides results in increased expression of IL12A mRNA CTD PMID:15998543 NCBI chr13:99,733,394...99,741,078
Ensembl chr13:99,733,394...99,741,078 		JBrowse link
G IL13 interleukin 13 increases expression EXP Lipopolysaccharides results in increased expression of IL13 mRNA CTD PMID:15998543 NCBI chr 2:134,972,099...134,976,672
Ensembl chr 2:134,972,623...134,975,093 		JBrowse link
G IL17A interleukin 17A multiple interactions EXP [deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein; fumonisin B1 inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein]; fumonisin B1 metabolite inhibits the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of IL17A protein] CTD PMID:30708112 NCBI chr 7:46,013,584...46,017,161
Ensembl chr 7:46,013,584...46,017,153 		JBrowse link
G IL1A interleukin 1 alpha multiple interactions
increases expression		 EXP ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]] CTD PMID:28528741 NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119 		JBrowse link
G IL6 interleukin 6 increases secretion
increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased secretion of IL6 protein
Lipopolysaccharides results in increased expression of IL6 mRNA
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; picolinic acid promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]		 CTD PMID:8724211 PMID:26180592 PMID:27861533 PMID:32877744 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263 		JBrowse link
G INS insulin decreases expression
multiple interactions		 EXP Lipopolysaccharides results in decreased expression of INS protein
GH1 protein inhibits the reaction [Lipopolysaccharides results in decreased expression of INS protein]		 CTD PMID:9185964 NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841 		JBrowse link
G LOC110258578 interleukin-1 beta-like multiple interactions
increases expression		 EXP [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] CTD PMID:37271275
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions
increases lipidation		 EXP deoxynivalenol inhibits the reaction [Lipopolysaccharides results in increased lipidation of MAP1LC3B protein]; MAP1LC3B protein affects the reaction [[deoxynivalenol co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] CTD PMID:32877744 NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions		 EXP Lipopolysaccharides results in increased phosphorylation of MAPK1 protein
ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]		 CTD PMID:28528741 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513 		JBrowse link
G MAPK14 mitogen-activated protein kinase 14 multiple interactions
increases expression		 EXP [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA] CTD PMID:37271275 NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation		 EXP ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] CTD PMID:28528741 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567 		JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member decreases expression EXP Lipopolysaccharides results in decreased expression of MCL1 mRNA CTD PMID:21645290 NCBI chr 4:98,562,092...98,567,014
Ensembl chr 4:98,534,812...98,567,006 		JBrowse link
G MYD88 MYD88 innate immune signal transduction adaptor increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of MYD88 mRNA; Lipopolysaccharides results in increased expression of MYD88 protein
ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of MYD88 protein]		 CTD PMID:28528741 NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109 		JBrowse link
G NCF1 neutrophil cytosolic factor 1 decreases expression EXP Lipopolysaccharides results in decreased expression of NCF1 mRNA CTD PMID:21645290 NCBI chr 3:11,820,367...11,834,394
Ensembl chr 3:11,820,266...11,839,354 		JBrowse link
G NCF2 neutrophil cytosolic factor 2 decreases expression EXP Lipopolysaccharides results in decreased expression of NCF2 mRNA CTD PMID:21645290 NCBI chr 9:124,776,516...124,813,358
Ensembl chr 9:124,776,534...124,812,923 		JBrowse link
G NCF4 neutrophil cytosolic factor 4 decreases expression EXP Lipopolysaccharides results in decreased expression of NCF4 mRNA CTD PMID:21645290 NCBI chr 5:10,876,147...10,994,002
Ensembl chr 5:10,874,953...10,994,014 		JBrowse link
G NFKBIA NFKB inhibitor alpha multiple interactions
decreases expression		 EXP deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein] CTD PMID:32877744 NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277 		JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions
increases expression		 EXP 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]
Lipopolysaccharides results in increased expression of NLRP3 mRNA; Lipopolysaccharides results in increased expression of NLRP3 protein		 CTD PMID:32877744 PMID:37271275 NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228 		JBrowse link
G NOS2 nitric oxide synthase 2 affects expression EXP Lipopolysaccharides affects the expression of NOS2 mRNA; Lipopolysaccharides affects the expression of NOS2 protein CTD PMID:12893242 NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146 		JBrowse link
G OCLN occludin multiple interactions
decreases expression		 EXP 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]]; [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of OCLN protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; theanine inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]
Lipopolysaccharides results in decreased expression of OCLN mRNA; Lipopolysaccharides results in decreased expression of OCLN protein		 CTD PMID:32877744 PMID:37271275 NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033 		JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 EXP Lipopolysaccharides results in increased expression of PTGS2 mRNA
3',4',5'-trimethoxyflavone analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Apigenin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]		 CTD PMID:26180592 PMID:27861533 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884 		JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit increases phosphorylation
multiple interactions		 EXP Lipopolysaccharides results in increased phosphorylation of RELA protein
[deoxynivalenol co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Flavones co-treated with Lipopolysaccharides] results in increased phosphorylation of RELA protein; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]; ochratoxin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]		 CTD PMID:28528741 PMID:31669396 PMID:32877744 NCBI chr 2:6,594,869...6,602,684
Ensembl chr 2:6,593,969...6,603,469 		JBrowse link
G ROCK1 Rho associated coiled-coil containing protein kinase 1 decreases expression EXP Lipopolysaccharides results in decreased expression of ROCK1 mRNA CTD PMID:21645290 NCBI chr 6:106,163,899...106,314,998
Ensembl chr 6:106,163,989...106,314,944 		JBrowse link
G SELE selectin E increases expression EXP Lipopolysaccharides results in increased expression of SELE CTD PMID:12224865 NCBI chr 4:81,289,061...81,299,657 JBrowse link
G SIRPA signal regulatory protein alpha affects expression EXP Lipopolysaccharides affects the expression of SIRPA mRNA CTD PMID:21645290 NCBI chr17:33,566,270...33,611,375 JBrowse link
G SIRT1 sirtuin 1 multiple interactions
decreases expression		 EXP 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]; Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein] CTD PMID:36549457 NCBI chr14:71,091,167...71,126,351
Ensembl chr14:71,091,167...71,123,297 		JBrowse link
G SLC38A1 solute carrier family 38 member 1 affects expression EXP Lipopolysaccharides affects the expression of SLC38A1 mRNA CTD PMID:21645290 NCBI chr 5:77,009,840...77,076,723
Ensembl chr 5:77,009,862...77,058,427 		JBrowse link
G SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 affects expression EXP Lipopolysaccharides affects the expression of SMARCA4 mRNA CTD PMID:21645290 NCBI chr 2:69,717,175...69,810,301
Ensembl chr 2:69,662,238...69,810,295 		JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions
decreases expression		 EXP Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SOD1 mRNA] CTD PMID:36549457 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729 		JBrowse link
G TGFB1 transforming growth factor beta 1 decreases expression
multiple interactions		 EXP Lipopolysaccharides results in decreased expression of TGFB1 mRNA
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TGFB1 mRNA]]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TGFB1 mRNA]; TGFB1 protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TGFB1 mRNA]]		 CTD PMID:32877744 NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,173...49,349,046 		JBrowse link
G TJP1 tight junction protein 1 decreases expression
multiple interactions		 EXP Lipopolysaccharides results in decreased expression of TJP1 mRNA; Lipopolysaccharides results in decreased expression of TJP1 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in decreased expression of TJP1 protein]]		 CTD PMID:32877744 NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836 		JBrowse link
G TLR4 toll like receptor 4 multiple interactions
increases expression		 EXP ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of IL1A mRNA]]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
Lipopolysaccharides results in increased expression of TLR4 mRNA; Lipopolysaccharides results in increased expression of TLR4 protein		 CTD PMID:15998543 PMID:28528741 NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970 		JBrowse link
G TNF tumor necrosis factor increases expression
increases secretion
multiple interactions		 EXP Lipopolysaccharides results in increased expression of TNF mRNA; Lipopolysaccharides results in increased expression of TNF protein
Lipopolysaccharides results in increased secretion of TNF protein
3',4',5'-trimethoxyflavone analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Lipopolysaccharides co-treated with fumonisin B1] results in increased expression of TNF protein; [laminaran co-treated with fucoidan co-treated with Minerals] promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Chlorogenic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; GH1 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; MAP1LC3B protein affects the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; picolinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; TLR4 protein affects the reaction [ochratoxin A promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]		 CTD PMID:9185964 PMID:12406900 PMID:21948611 PMID:26180592 PMID:27861533 More... NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416 		JBrowse link
lipoteichoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G IFNG interferon gamma increases expression EXP lipoteichoic acid results in increased expression of IFNG mRNA CTD PMID:15998543 NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670 		JBrowse link
G IL10 interleukin 10 increases expression EXP lipoteichoic acid results in increased expression of IL10 mRNA CTD PMID:15998543 NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378 		JBrowse link
G IL12A interleukin 12A increases expression EXP lipoteichoic acid results in increased expression of IL12A mRNA CTD PMID:15998543 NCBI chr13:99,733,394...99,741,078
Ensembl chr13:99,733,394...99,741,078 		JBrowse link
G IL13 interleukin 13 increases expression EXP lipoteichoic acid results in increased expression of IL13 mRNA CTD PMID:15998543 NCBI chr 2:134,972,099...134,976,672
Ensembl chr 2:134,972,623...134,975,093 		JBrowse link
G TLR4 toll like receptor 4 increases expression EXP lipoteichoic acid results in increased expression of TLR4 mRNA CTD PMID:15998543 NCBI chr 1:258,044,610...258,054,641
Ensembl chr 1:258,044,610...258,058,970 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 5066
    chemical entity 5066
      molecular entity 5065
        polyatomic entity 5045
          macromolecule 67
            biomacromolecule 62
              polysaccharide derivative 62
                A. baumannii strain 54149 exopolysaccharide 0
                A. haemolyticus strain 57 O-specific polysaccharide 0
                A. haemolyticus strain 61 O-specific polysaccharide 0
                Brucella sp. O-PS M-antigen 0
                E. coli 180/C3 O-specific polysaccharide 0
                E. coli O5:K4:H4 O-specific polysaccharide 0
                E. coli O65:K-:H- O-specific polysaccharide 0
                Glc(a1-2)Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc 0
                Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc + 0
                GlyTouCan G80920RR 0
                GlyTouCan G93860XO 0
                H. influenzae type B capsular polysaccharide 0
                K antigen 0
                Legionella pneumophila O-specific polysaccharide 0
                Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc + 0
                N-glycan derivative + 0
                N. meningitidis group C polysaccharide 0
                O-polysaccharide + 52
                P. mirabilis 9B-m O-specific polysaccharide 0
                P. mirabilis O11 O-specific polysaccharide 0
                P. mirabilis O24 O-specific polysaccharide 0
                P. mirabilis O29 O-specific polysaccharide 0
                P. mirabilis O43 O-specific polysaccharide 0
                P. mirabilis O6 O-specific polysaccharide 0
                P. stuartii O33 O-specific polysaccharide 0
                P. stuartii O4 O-specific polysaccharide 0
                PCM 2476 oligosaccharide 0
                PCM 2477 oligosaccharide 0
                Proteus genomospecies 3J-r O-specific polysaccharide 0
                S. flexneri Y polysaccharide 0
                S. flexneri serotype 1a O-polysaccharide (O factor 9-negative) 0
                S. flexneri serotype 1a O-polysaccharide (O factor 9-positive) 0
                S. flexneri serotype 1b O-polysaccharide (O factor 9-positive) 0
                S. flexneri serotype 2a O-polysaccharide (O factor 9-negative) 0
                S. flexneri serotype 2a O-polysaccharide (O factor 9-positive) 0
                S. flexneri serotype 2a O-specific polysaccharide 0
                S. flexneri serotype 2b O-specific polysaccharide 0
                S. flexneri serotype 3a O-specific polysaccharide 0
                S. flexneri serotype 5a O-polysaccharide (O factor 9-negative) 0
                S. flexneri serotype 5a O-polysaccharide (O factor 9-positive) 0
                S. flexneri serotype 5a O-specific polysaccharide 0
                S. flexneri serotype 5b O-specific polysaccharide 0
                S. flexneri serotype 6 O-polysaccharide (O factor 9-positive) 0
                S. flexneri serotype X O-specific polysaccharide 0
                S. flexneri serotype Y O-polysaccharide (O factor 9-negative) 0
                S. flexneri serotype Y O-polysaccharide (O factor 9-positive) 0
                [2)-[Abep(2Ac)-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap2/3Ac-(1->3)-[alpha-D-Glcp-(1->4/6)]-alpha-D-Galp-(1->]n 0
                [2)-[Tyvp-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4/6)]-alpha-D-Galp-(1->]n 0
                [2)-alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-alpha-D-GalpNAc-(1->]n 0
                [2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->]n 0
                [2)-beta-QuiN4Fm-(1->4)-alpha-GalNAcAN-(1->4)-alpha-GalNAcAN-(1->3)-beta-QuiNAc-(1->2)-beta-QuiN4Fm-(1->4)-alpha-GalNAcAN-(1->4)-alpha-GalNAcAN-(1->3)-beta-QuiNAc-(1->]n 0
                [2)-beta-QuiN4Fm-(1->4)-alpha-GalNAcAN-(1->4)-alpha-GalNAcAN-(1->3)-beta-QuiNAc-(1->]n 0
                [3)-alpha-D-Fucp4N,NAc-(1->4)-alpha-D-GalpA-(1->3)-alpha-D-GalpA-(1->]n 0
                [3)-beta-D-Galp-(1->3)-alpha-D-Galp-(1->]n-[3)-beta-D-Galf-(1->3)-alpha-D-Galp-(1->]n 0
                [3)-beta-D-Galp-(1->4)-[alpha-D-Glcp-(1->3)]-beta-D-Manp-(1->4)-beta-D-Glcp-(1->]n 0
                [3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->]n 0
                [3)-beta-D-GlcpNAc-(1->4)-alpha-L-Rhap-(1->]n 0
                [3)-beta-D-Manp4,NAc2A-(1->3)-alpha-L-FucpNAc-(1->3)-alpha-D-FucpNAc-(1->]n 0
                [3)-beta-D-ManpNAcA-(1->3)-alpha-L-FucpNAc-(1->3)-alpha-D-FucpNAc-(1->]n 0
                [3)-beta-D-QuipNAc4NAc-(1->3)-beta-D-GlcpNAmA-(1->]n 0
                [3)-beta-D-galactopyranuronosyl-(1->3)-2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-glucopyranosyl-(1->4)-beta-D-galactopyranurosyl-(1->]n 0
                [4)-D-GlcpA-(1->4)-D-GlcpNAc-(1->]n 0
                [4)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                [4)-[alpha-Neup5Ac-(2->6)-beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                [4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                [4)-[beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                [4)-[beta-D-Glcp-(1->6)]-[alpha-L-Rhap-(1->3)]-alpha-D-Glcp-(1->3)-alpha-L-Rhap2Ac-(1->3)-beta-D-GlcpNAc-(1->]n 0
                [4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-D-QuiNAc-(1->2)-beta-D-QuiN4Fm-(1->4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->]n 0
                [4)-alpha-D-Glcp-(1->4)-alpha-D-Galp-(1->4)-beta-D-GlcpA-(1->4)-beta-D-Glcp-(1->]n 0
                [4)-alpha-L-GulpNAc3NAcA-(1->4)-betaManpNAc3NAcA-(1->]n 0
                [4)-beta-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->]n 0
                [4)-beta-D-ManpNAcA-(1->4)-alpha-L-Fucp3,NAc2-(1->3)-beta-D-FucpNAc-(1->]n + 0
                [6)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                [6)-[alpha-Neup5Ac-(2->6)-beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                [6)-[beta-D-Galp-(1->2)]-alpha-D-Galp-(1->3)-beta-L-Rhap2Ac-(1->4)-beta-D-Glcp-(1->3)-[alpha-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->4)]-beta-D-GalpNAc-(1->]n 0
                [6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                [6)-[beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                [6)-alpha-D-Galp-(1->4)-alpha-D-NeupAc-(2->]n 0
                [6)-alpha-D-GlcNAc-(1->4)-alpha-D-GalA-(1->3)-alpha-D-GlcNAc-(1->3)-beta-D-Qui4N(Ac-L-Asp)-(1->]n 0
                [6)-alpha-D-Glcp-(1->4)-alpha-D-Neup5,7Ac2-(2->]n 0
                [6)-alpha-D-Glcp-(1->4)-alpha-D-NeupAc-(2->]n 0
                [8)-alpha-Neu5Ac-(2->9)-alpha-Neu5Ac-(2->]n 0
                [8)-alpha-Neu5Ac-(2->]14 0
                [8)-alpha-Neu5Pr-(2->]14 0
                [9)-alpha-Neu5,7,8Ac3-(2->]n 0
                [9)-alpha-Neu5Ac-(2->]n 0
                \{2)-L-Fucp-(1->4)-[L-Fucp-(1->3)]-L-GlcpNAc-(1->\}n 0
                \{3)-[beta-D-GlcpNAc-(1->4)]-alpha-D-Rhap-(1->3)-alpha-D-Rhap-(1->2)-alpha-D-Rhap-(1->2)-alpha-D-Rhap-(1->\}n 0
                \{3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->\}n 0
                \{4)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1->\}n 0
                \{4)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Glcp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->\}n 0
                \{4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1->\}n 0
                \{4)-beta-D-Glc-(1->6)-[alpha-D-NeuNAc-(2->3)-beta-D-Gal-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->\}n 0
                \{6)-[beta-D-Gal-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1->\}n 0
                \{6)-[beta-D-GlcpA-(1->3)]-beta-D-GalpNAc-(1->\}n 0
                agaropectin + 0
                alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc 0
                alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc 0
                aminoglycan + 7
                amylopectin + 0
                beta-2,6-Pse-linked A. baumannii strain 54149 exopolysaccharide 0
                beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc + 0
                carboxymethyl-pachyman 0
                carboxymethylcellulose 0
                colanic acid 0
                curamycin A 0
                enterobacterial common antigen 0
                feruloyl-polysaccharide 0
                feruloyl-polysaccharides 0
                galacturonan derivative + 0
                glucuronoxylomannan 0
                heparin dodecasaccharide + 0
                heparin hexadecasaccharide + 0
                heparin icosasaccharide + 0
                heparin tetradecasaccharide + 0
                homopolysaccharide derivative + 0
                hydroxyethylcellulose 0
                hydroxypropyl methylcellulose 0
                lipopolysaccharide + 52
                momordicoside B 0
                momordicoside T 0
                poly-ADP-D-ribose 0
                polysaccharide phosphate + 0
                polysaccharide sulfate + 6
                proteoglycan + 0
                succinoglucan 0
                teichoic acid + 5
                type Ib group B Streptococcus capsular polysaccharide 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 5066
    subatomic particle 5057
      composite particle 5057
        hadron 5057
          baryon 5057
            nucleon 5057
              atomic nucleus 5057
                atom 5057
                  main group element atom 5026
                    p-block element atom 5023
                      carbon group element atom 4940
                        carbon atom 4939
                          organic molecular entity 4939
                            heteroorganic entity 4779
                              organochalcogen compound 4741
                                organooxygen compound 4703
                                  carbohydrates and carbohydrate derivatives 123
                                    carbohydrate 123
                                      polysaccharide 62
                                        polysaccharide derivative 62
                                          A. baumannii strain 54149 exopolysaccharide 0
                                          A. haemolyticus strain 57 O-specific polysaccharide 0
                                          A. haemolyticus strain 61 O-specific polysaccharide 0
                                          Brucella sp. O-PS M-antigen 0
                                          E. coli 180/C3 O-specific polysaccharide 0
                                          E. coli O5:K4:H4 O-specific polysaccharide 0
                                          E. coli O65:K-:H- O-specific polysaccharide 0
                                          Glc(a1-2)Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc 0
                                          Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc + 0
                                          GlyTouCan G80920RR 0
                                          GlyTouCan G93860XO 0
                                          H. influenzae type B capsular polysaccharide 0
                                          K antigen 0
                                          Legionella pneumophila O-specific polysaccharide 0
                                          Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc + 0
                                          N-glycan derivative + 0
                                          N. meningitidis group C polysaccharide 0
                                          O-polysaccharide + 52
                                          P. mirabilis 9B-m O-specific polysaccharide 0
                                          P. mirabilis O11 O-specific polysaccharide 0
                                          P. mirabilis O24 O-specific polysaccharide 0
                                          P. mirabilis O29 O-specific polysaccharide 0
                                          P. mirabilis O43 O-specific polysaccharide 0
                                          P. mirabilis O6 O-specific polysaccharide 0
                                          P. stuartii O33 O-specific polysaccharide 0
                                          P. stuartii O4 O-specific polysaccharide 0
                                          PCM 2476 oligosaccharide 0
                                          PCM 2477 oligosaccharide 0
                                          Proteus genomospecies 3J-r O-specific polysaccharide 0
                                          S. flexneri Y polysaccharide 0
                                          S. flexneri serotype 1a O-polysaccharide (O factor 9-negative) 0
                                          S. flexneri serotype 1a O-polysaccharide (O factor 9-positive) 0
                                          S. flexneri serotype 1b O-polysaccharide (O factor 9-positive) 0
                                          S. flexneri serotype 2a O-polysaccharide (O factor 9-negative) 0
                                          S. flexneri serotype 2a O-polysaccharide (O factor 9-positive) 0
                                          S. flexneri serotype 2a O-specific polysaccharide 0
                                          S. flexneri serotype 2b O-specific polysaccharide 0
                                          S. flexneri serotype 3a O-specific polysaccharide 0
                                          S. flexneri serotype 5a O-polysaccharide (O factor 9-negative) 0
                                          S. flexneri serotype 5a O-polysaccharide (O factor 9-positive) 0
                                          S. flexneri serotype 5a O-specific polysaccharide 0
                                          S. flexneri serotype 5b O-specific polysaccharide 0
                                          S. flexneri serotype 6 O-polysaccharide (O factor 9-positive) 0
                                          S. flexneri serotype X O-specific polysaccharide 0
                                          S. flexneri serotype Y O-polysaccharide (O factor 9-negative) 0
                                          S. flexneri serotype Y O-polysaccharide (O factor 9-positive) 0
                                          [2)-[Abep(2Ac)-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap2/3Ac-(1->3)-[alpha-D-Glcp-(1->4/6)]-alpha-D-Galp-(1->]n 0
                                          [2)-[Tyvp-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4/6)]-alpha-D-Galp-(1->]n 0
                                          [2)-alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-alpha-D-GalpNAc-(1->]n 0
                                          [2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->]n 0
                                          [2)-beta-QuiN4Fm-(1->4)-alpha-GalNAcAN-(1->4)-alpha-GalNAcAN-(1->3)-beta-QuiNAc-(1->2)-beta-QuiN4Fm-(1->4)-alpha-GalNAcAN-(1->4)-alpha-GalNAcAN-(1->3)-beta-QuiNAc-(1->]n 0
                                          [2)-beta-QuiN4Fm-(1->4)-alpha-GalNAcAN-(1->4)-alpha-GalNAcAN-(1->3)-beta-QuiNAc-(1->]n 0
                                          [3)-alpha-D-Fucp4N,NAc-(1->4)-alpha-D-GalpA-(1->3)-alpha-D-GalpA-(1->]n 0
                                          [3)-beta-D-Galp-(1->3)-alpha-D-Galp-(1->]n-[3)-beta-D-Galf-(1->3)-alpha-D-Galp-(1->]n 0
                                          [3)-beta-D-Galp-(1->4)-[alpha-D-Glcp-(1->3)]-beta-D-Manp-(1->4)-beta-D-Glcp-(1->]n 0
                                          [3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->]n 0
                                          [3)-beta-D-GlcpNAc-(1->4)-alpha-L-Rhap-(1->]n 0
                                          [3)-beta-D-Manp4,NAc2A-(1->3)-alpha-L-FucpNAc-(1->3)-alpha-D-FucpNAc-(1->]n 0
                                          [3)-beta-D-ManpNAcA-(1->3)-alpha-L-FucpNAc-(1->3)-alpha-D-FucpNAc-(1->]n 0
                                          [3)-beta-D-QuipNAc4NAc-(1->3)-beta-D-GlcpNAmA-(1->]n 0
                                          [3)-beta-D-galactopyranuronosyl-(1->3)-2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-glucopyranosyl-(1->4)-beta-D-galactopyranurosyl-(1->]n 0
                                          [4)-D-GlcpA-(1->4)-D-GlcpNAc-(1->]n 0
                                          [4)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                                          [4)-[alpha-Neup5Ac-(2->6)-beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                                          [4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                                          [4)-[beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-D-Galp-(1->3)]-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->]n 0
                                          [4)-[beta-D-Glcp-(1->6)]-[alpha-L-Rhap-(1->3)]-alpha-D-Glcp-(1->3)-alpha-L-Rhap2Ac-(1->3)-beta-D-GlcpNAc-(1->]n 0
                                          [4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-D-QuiNAc-(1->2)-beta-D-QuiN4Fm-(1->4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->]n 0
                                          [4)-alpha-D-Glcp-(1->4)-alpha-D-Galp-(1->4)-beta-D-GlcpA-(1->4)-beta-D-Glcp-(1->]n 0
                                          [4)-alpha-L-GulpNAc3NAcA-(1->4)-betaManpNAc3NAcA-(1->]n 0
                                          [4)-beta-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->]n 0
                                          [4)-beta-D-ManpNAcA-(1->4)-alpha-L-Fucp3,NAc2-(1->3)-beta-D-FucpNAc-(1->]n + 0
                                          [6)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                                          [6)-[alpha-Neup5Ac-(2->6)-beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                                          [6)-[beta-D-Galp-(1->2)]-alpha-D-Galp-(1->3)-beta-L-Rhap2Ac-(1->4)-beta-D-Glcp-(1->3)-[alpha-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->4)]-beta-D-GalpNAc-(1->]n 0
                                          [6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                                          [6)-[beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->]n 0
                                          [6)-alpha-D-Galp-(1->4)-alpha-D-NeupAc-(2->]n 0
                                          [6)-alpha-D-GlcNAc-(1->4)-alpha-D-GalA-(1->3)-alpha-D-GlcNAc-(1->3)-beta-D-Qui4N(Ac-L-Asp)-(1->]n 0
                                          [6)-alpha-D-Glcp-(1->4)-alpha-D-Neup5,7Ac2-(2->]n 0
                                          [6)-alpha-D-Glcp-(1->4)-alpha-D-NeupAc-(2->]n 0
                                          [8)-alpha-Neu5Ac-(2->9)-alpha-Neu5Ac-(2->]n 0
                                          [8)-alpha-Neu5Ac-(2->]14 0
                                          [8)-alpha-Neu5Pr-(2->]14 0
                                          [9)-alpha-Neu5,7,8Ac3-(2->]n 0
                                          [9)-alpha-Neu5Ac-(2->]n 0
                                          \{2)-L-Fucp-(1->4)-[L-Fucp-(1->3)]-L-GlcpNAc-(1->\}n 0
                                          \{3)-[beta-D-GlcpNAc-(1->4)]-alpha-D-Rhap-(1->3)-alpha-D-Rhap-(1->2)-alpha-D-Rhap-(1->2)-alpha-D-Rhap-(1->\}n 0
                                          \{3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->\}n 0
                                          \{4)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1->\}n 0
                                          \{4)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Glcp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->\}n 0
                                          \{4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1->\}n 0
                                          \{4)-beta-D-Glc-(1->6)-[alpha-D-NeuNAc-(2->3)-beta-D-Gal-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->\}n 0
                                          \{6)-[beta-D-Gal-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1->\}n 0
                                          \{6)-[beta-D-GlcpA-(1->3)]-beta-D-GalpNAc-(1->\}n 0
                                          agaropectin + 0
                                          alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc 0
                                          alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc 0
                                          aminoglycan + 7
                                          amylopectin + 0
                                          beta-2,6-Pse-linked A. baumannii strain 54149 exopolysaccharide 0
                                          beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc + 0
                                          carboxymethyl-pachyman 0
                                          carboxymethylcellulose 0
                                          colanic acid 0
                                          curamycin A 0
                                          enterobacterial common antigen 0
                                          feruloyl-polysaccharide 0
                                          feruloyl-polysaccharides 0
                                          galacturonan derivative + 0
                                          glucuronoxylomannan 0
                                          heparin dodecasaccharide + 0
                                          heparin hexadecasaccharide + 0
                                          heparin icosasaccharide + 0
                                          heparin tetradecasaccharide + 0
                                          homopolysaccharide derivative + 0
                                          hydroxyethylcellulose 0
                                          hydroxypropyl methylcellulose 0
                                          lipopolysaccharide + 52
                                          momordicoside B 0
                                          momordicoside T 0
                                          poly-ADP-D-ribose 0
                                          polysaccharide phosphate + 0
                                          polysaccharide sulfate + 6
                                          proteoglycan + 0
                                          succinoglucan 0
                                          teichoic acid + 5
                                          type Ib group B Streptococcus capsular polysaccharide 0
paths to the root